An observational study in Hemodialysis and End Stage Renal Disease (ESRD), sponsored by Kirsehir Ahi Evran Universitesi. Recruiting at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.
Sponsored by Kirsehir Ahi Evran Universitesi · Observational
The aim of our study was to investigate the relationship between kinesiophobia and pain, balance, physical performance, quality of life and mental status in patients receiving hemodialysis.
2,085 studies on the registry are indexed under Kidney Failure, Chronic; 260 are open to participants now.
This study's planned enrollment of 32 is below the median of 120 across 431 observational studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →Kirsehir Ahi Evran Universitesi is the lead sponsor of 133 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with end-stage renal disease receiving hemodialysis will be enrolled in the study.
Exclusion Criteria:
-Having musculoskeletal disorders that may affect physical performance
Kinesiophobia
It will be evaluated with the Tampa Kinesiophobia scale.The total score ranges from 17-68, with a score above 37 indicating a high degree of kinesiophobia.
Time frame: Day 1
Pain
Will be evaluated with a numeric rating scale. Higher scores indicate worse outcomes.
Time frame: Day 1
Balance
It will be assessed with a timed up and go test
Time frame: Day 1
Physical performance
It will be evaluated with five-repetition sit-to-stand test
Time frame: Day 1
Quality of life
It will be evaluated with the Short Form-36 Quality of Life scale.The subscales rate health from 0 to 100, with 0 indicating poor health and 100 indicating good health.
Time frame: Day 1
Mental health
It will be assessed using the Hospital Anxiety and Depression scale. The lowest score they can get from both subscales is 0 and the highest score is 21.High scores indicate high levels of anxiety and depression
Time frame: Day 1
Comorbidity level
It will be evaluated with the Charlson Comorbidity Index. Total score is between 0-37. Higher scores indicate worse outcomes and higher risk of death.
Time frame: Day 1
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kirsehir Ahi Evran Universitesi